TGFB1 and scleroderma: In clinical trials, a TGFβ1 inhibitor and a monoclonal antibody against TGFβ1 were found to be ineffective in the treatment of scleroderma and systemic sclerosis, and human recombinant TGFβ3 failed in a phase III clinical trial on human scarring57.